M E Ketelaar1,2,3, M C Nawijn2, D E Shaw1, G H Koppelman3, I Sayers1. 1. Division of Respiratory Medicine, University of Nottingham, Nottingham, UK. 2. University Medical Center Groningen, Department of Pathology and Medical Biology, Laboratory of Allergology and Pulmonary Diseases, University of Groningen, Groningen, The Netherlands. 3. University Medical Center Groningen, Pediatric Pulmonology and Pediatric Allergology, Beatrix Children's Hospital, Groningen Research Institute for Asthma and COPD, University of Groningen, Groningen, The Netherlands.
Abstract
BACKGROUND: Interleukin-33 (IL-33) has been subject of extensive study in the context of inflammatory disorders, particularly in asthma. Many human biological samples, including serum, have been used to determine the protein levels of IL-33, aiming to investigate its involvement in asthma. Reliable methods are required to study the association of IL-33 with disease, especially considering the complex nature of serum samples. OBJECTIVE: We evaluated four IL-33 ELISA kits, aiming to determine a robust and reproducible approach to quantifying IL-33 in human serum from asthma patients. METHODS: IL-33 levels were investigated in serum of well-defined asthma patients by the Quantikine, DuoSet (both R&D systems), ADI-900-201 (Enzo Life Sciences), and SKR038 (GenWay Biotech Inc San Diego USA) immunoassays, as well as spiking experiments were performed using recombinant IL-33 and its soluble receptor IL-1RL1-a. RESULTS: We show that 1) IL-33 is difficult to detect by ELISA in human serum, due to lack of sensitivity and specificity of currently available assays; 2) human serum interferes with IL-33 quantification, in part through IL-1RL1-a; and 3) using non-serum certified kits may lead to spurious findings. CONCLUSION AND CLINICAL RELEVANCE: If IL-33 is to be studied in the serum of asthma patients and other diseases, a more sensitive and specific assay method is required, which will be vital for further understanding and targeting of the IL-33/IL-1RL1 axis in human disease.
BACKGROUND:Interleukin-33 (IL-33) has been subject of extensive study in the context of inflammatory disorders, particularly in asthma. Many human biological samples, including serum, have been used to determine the protein levels of IL-33, aiming to investigate its involvement in asthma. Reliable methods are required to study the association of IL-33 with disease, especially considering the complex nature of serum samples. OBJECTIVE: We evaluated four IL-33 ELISA kits, aiming to determine a robust and reproducible approach to quantifying IL-33 in human serum from asthmapatients. METHODS:IL-33 levels were investigated in serum of well-defined asthmapatients by the Quantikine, DuoSet (both R&D systems), ADI-900-201 (Enzo Life Sciences), and SKR038 (GenWay Biotech Inc San Diego USA) immunoassays, as well as spiking experiments were performed using recombinant IL-33 and its soluble receptor IL-1RL1-a. RESULTS: We show that 1) IL-33 is difficult to detect by ELISA in human serum, due to lack of sensitivity and specificity of currently available assays; 2) human serum interferes with IL-33 quantification, in part through IL-1RL1-a; and 3) using non-serum certified kits may lead to spurious findings. CONCLUSION AND CLINICAL RELEVANCE: If IL-33 is to be studied in the serum of asthmapatients and other diseases, a more sensitive and specific assay method is required, which will be vital for further understanding and targeting of the IL-33/IL-1RL1 axis in human disease.
Authors: Gregory S Whitehead; Seddon Y Thomas; Karim H Shalaby; Keiko Nakano; Timothy P Moran; James M Ward; Gordon P Flake; Hideki Nakano; Donald N Cook Journal: J Clin Invest Date: 2017-07-31 Impact factor: 14.808
Authors: Markus Kieler; Matthias Unseld; Johann Wojta; Alexandra Kaider; Daniela Bianconi; Svitlana Demyanets; Gerald W Prager Journal: Med Oncol Date: 2018-11-13 Impact factor: 3.064
Authors: Olav Sundnes; William Ottestad; Guttorm Haraldsen; Torsten Eken; Camilla Schjalm; Peter Lundbäck; Lars la Cour Poulsen; Tom Eirik Mollnes Journal: Mol Med Date: 2021-03-26 Impact factor: 6.354
Authors: Stefan Stojkovic; Svitlana Demyanets; Christoph W Kopp; Christian Hengstenberg; Johann Wojta; Beate Eichelberger; Simon Panzer; Thomas Gremmel Journal: Front Cardiovasc Med Date: 2020-12-22